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Abstract
Background: The production of β-lactamases by bacteria is the most common mechanism of resistance to the widely
prescribed β-lactam antibiotics. β-lactamase inhibitory protein (BLIP) competitively inhibits class A β-lactamases via two
binding loops that occlude the active site. It has been shown that BLIP Tyr50 is a specificity determinant in
that substitutions at this position result in large differential changes in the relative affinity of BLIP for class A β-lactamases.
Results: In this study, the effect of systematic substitutions at BLIP position 50 on binding to class A β-lactamases was
examined to further explore the role of BLIP Tyr50 in modulating specificity. The results indicate the sequence
requirements at position 50 are widely different depending on the target β-lactamase. Stringent sequence requirements
were observed at Tyr50 for binding Bacillus anthracis Bla1 while moderate requirements for binding TEM-1 and relaxed
requirements for binding KPC-2 β-lactamase were seen. These findings cannot be easily rationalized based on
the β-lactamase residues in direct contact with BLIP Tyr50 since they are identical for Bla1 and KPC-2 suggesting that
differences in the BLIP-β-lactamase interface outside the local environment of Tyr50 influence the effect of substitutions.
Conclusions: Results from this study and previous studies suggest that substitutions at BLIP Tyr50 may induce changes
at the interface outside its local environment and point to the complexity of predicting the impact of substitutions at a
protein-protein interaction interface.
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Background
Interactions between proteins play an essential role in
nearly every cellular process. Each protein in a cell is esti-
mated to interact with approximately five other proteins,
forming a complex interaction network [1]. A better un-
derstanding of protein-protein interactions, in particular
what regulates rates of formation and dissociation and the
molecular basis of specificity, would have applications ran-
ging across fields from protein engineering to drug design
[2]. Numerous protein-protein interactions have been stud-
ied and provide details about the roles of shape comple-
mentarity, long- and short-range interactions and solvent
in binding [3–10]. However, even with this large accumula-
tion of data, prediction programs often have limited suc-
cess, largely because of challenges posed by cooperativity
between residues, flexibility, and rearrangement at the
large, multifaceted interface upon binding [5, 11]. Some
success has been shown for predicting changes upon muta-
tion to alanine; however, predicting the effects of mutations
to the other 19 amino acids often falls short because resi-
dues other than alanine lose interactions and also have the
ability to form new ones. It is important to understand
how mutations to all possible amino acids modify protein-
protein interactions for protein engineering and because
mutations other than alanine are frequently seen in nature.
Various protein-protein complexes such as BLIP and
β-lactamases have developed into model systems to
examine the basic principles underlying protein-protein
interactions [6, 7, 12–15]. Studies of a variety of protein
complexes indicate that only a subset of residues at the
interface contributes substantially to binding affinity and
these residues are termed “hot spots” [12, 13, 16–19].
Specificity determinants, i.e., residues where energetic
contributions vary depending on the binding partners,
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were found among the hot spot residues in the BLIP-
β-lactamase interaction [12]. Specificity determinants
are of particular interest because of their ability to exhibit
a significantly different effect on binding affinity to differ-
ent protein binding partners when mutated. For example,
when BLIP Tyr50 was mutated to alanine it exhibited a
50-fold increase in binding affinity for one binding partner
(TEM-1) and a 65-fold decrease in binding affinity for an-
other (Sme-1) (Table 1) [12].
The current study focuses on further examination of the
specificity determinant BLIP Tyr50 in the interaction of
BLIP with various class A β-lactamases. BLIP is a 17.5 kDa
protein produced from the soil bacterium Streptomyces
clavuligerus that inhibits class A β-lactamases with varying
affinities (subnanomolar to micromolar) (Table 1) [20–22].
Class A β-lactamases hydrolyze the commonly prescribed
β-lactam antibiotics rendering them inactive [23]. The pro-
duction of β-lactamases is the most common mechanism
of bacterial resistance in Gram-negative bacteria [23]. BLIP
inhibits class A β-lactamases by docking its predominantly
polar, concave surface onto the enzyme, burying approxi-
mately 2,600 Å2 of surface area [22]. BLIP competitively
inhibits class A β-lactamases via two binding loops that
occlude the active site of the enzymes (Fig. 1a & b) [22].
The tertiary structures of class A β-lactamases are hom-
ologous but the sequences vary in identity from 30-70%
(Fig. 2) (Table 2) [23].
BLIP positions Tyr50, Glu73, Lys74 and Tyr143 were
previously identified as specificity determinants in that
substitutions at these positions result in large changes in
the relative affinity of BLIP for various class A β-
lactamases [13]. BLIP Tyr50 resides on the 46-53 loop that
contains two hotspots for binding – Asp49 and Tyr53
[13]. A concerted rearrangement occurs at both interfaces
upon binding of BLIP and TEM-1 β-lactamase; of particu-
lar interest, TEM-1 Tyr105 rearranges upon complex for-
mation to relieve a steric clash with BLIP Tyr50 (Fig. 1c)
[16, 22, 24]. In addition, residue 105, which is tryptophan
in KPC-2 β-lactamase, is in a similar position as Tyr105 of
TEM-1 and also undergoes a rearrangement in the BLIP-
KPC-2 complex (Fig. 1d) [25]. This rearrangement of β-
lactamase position 105 may be a contributing factor to
changes in binding affinity upon mutation of BLIP Tyr50.
BLIP Tyr50 forms van der Waals contacts with the β3
strand of TEM-1 and KPC-2, and also interacts directly
with positions 107, 129 and 216 on the β-lactamase inter-
face (Fig. 2) [16, 22]. A structural alignment of the
positions on the β-lactamase interface is shown in Fig. 2
with TEM-1 and KPC-2 from the apo form and Bla1 from
a BLIP-II bound form as no apo structure of Bla1 is avail-
able [26]. β-lactamase positions 107, 129 and 216 have the
same sequence and similar structure for Bla1 and KPC-2
while TEM-1 differs at positions 129 and 216 (Fig. 2). As
discussed above and seen in Fig. 2, the Tyr105 and Trp105
residues of TEM-1 and KPC-2 are in a similar position in
apo forms of the enzyme. The Tyr105 residue of Bla1 is in
an altered position in the structural alignment, however,
this is likely due to the structure originating from the
BLIP-II-Bla1 complex (Fig. 2) [26].
In this study, the effect of systematic substitutions at
BLIP Tyr50 is examined using kinetic analysis to deter-
mine how specificity can be modulated for binding
TEM-1, KPC-2 and Bla1 β-lactamases. These experi-
ments were also performed computationally to assess
the current success rate of an available protein binding
prediction program. A deeper understanding of the in-
teractions of BLIP with β-lactamases offers an opportun-
ity to explore how specificity can be introduced into
proteins rationally, by design.
Results
Determination of inhibition constants for β-lactamases
BLIP Y50 was substituted to all 19 amino acids to inves-
tigate the role of this residue in modulating specificity.
The mutant proteins were purified (with the exception
of BLIP Y50I which could not be purified due to low ex-
pression and yield) and assayed with TEM-1, KPC-2 and
Bla1 β-lactamases to determine the inhibition constants
(Table 3, Fig. 3). It was previously reported that the BLIP
Y50A substitution alters the binding specificity for β-
lactamases; however, the extent to which other substitu-
tions at position 50 alter binding specificity is unknown.
Overall, the results of this study support the hypothesis
that BLIP Y50 makes important contributions to the bind-
ing specificity of BLIP for class A β-lactamases.
BLIP is a potent inhibitor of each of the β-lactamases
studied with Ki values of 0.5 nM for TEM-1, 1.5 nM for
KPC-2 and 2.5 nM for Bla2 (Table 3). The effect of sub-
stitutions at BLIP Y50 on the binding affinity for the
enzymes, however, is widely different. Most BLIP Y50
substitutions retain tight binding for KPC-2 while many
substitutions reduce binding to TEM-1 and the majority
of substitutions are detrimental for binding Bla1
(Table 3). This is apparent from the finding that only 3
substitutions result in a greater than 10-fold loss in
affinity for KPC-2 while 10 substitutions reduce binding
by >10-fold for TEM-1 and 15 result in a >10-fold loss
in affinity for Bla1 (Table 3). The changes in binding
constants for the substitutions were normalized by cal-
culating the changes in free energy of the complex using
the following equation: ΔΔG= -RT ln (Ki
WT / Ki
MUT)
Table 1 Binding Constants of BLIP and BLIPY50A for Class A β-
lactamases
BLIP Ki (nM) TEM-1 Ki (nM) SHV-1 Ki (nM) Sme-1
WT 0.5a 1130a 2.4a
Y50A 0.011a 34a 32a
avalues from Zhang Z, et al. [13]
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(Table 4). A negative ΔΔG value is indicative of an in-
crease in binding affinity as compared to wild type while
a positive value corresponds to a decrease in binding af-
finity. Using these values, the wide difference in toler-
ance to BLIP Y50 substitutions for binding β-lactamases
is clear in that the average effect of substitutions (ΔΔG)
on binding KPC-2 was 0.7 kcal/mol while that for bind-
ing TEM-1 was 1.3 kcal/mol and that for binding Bla1
was 2.3 kcal/mol (Table 4 and Fig. 4). These results indi-
cate that the sequence requirements at BLIP position 50
are significantly less stringent for binding KPC-2 com-
pared to the requirements for binding TEM-1 and Bla1.
Examination of the substitution results in Tables 3 and
4 reveals some common sequence requirements at BLIP
position 50 for binding all three β-lactamases. For
example, cysteine, phenylalanine and lysine substitutions
showed a greater than 10-fold decrease in binding affin-
ity for all three enzymes (Table 3). Cysteine may de-
crease binding affinity because of the potential of being
oxidized, which would disrupt binding. Phenylalanine
has a similar van der Waals volume as the wild-type
tyrosine residue but does not have the hydrogen
bonding capacity and could potentially interrupt the
organization of structural waters at the interface be-
cause of its strong hydrophobic properties. The de-
crease in binding affinity when lysine is substituted at
BLIP position 50 is likely due to introduction of an
unpaired charge in the interface. Although lysine was
the only charged residue to globally decrease binding
affinity by 10-fold, the general finding is that charged
Fig. 1 Structural representation of the interaction between BLIP and β-lactamases. BLIP is shown as a purple ribbon with Tyr50BLIP shown as stick.
TEM-1 a and KPC-2 b β-lactamases are shown as white spheres with the catalytic Ser70 in yellow and positions 107, 129 and 216 (that make contact with
Tyr50BLIP) are shown in red. PDB codes: 1JTG and 3E2K. Alignment of apo (gray) and bound (white) TEM-1 c and KPC-2 d structures shown in ribbon with
position 105β-lactamase shown as stick. BLIPY50 is shown as a purple stick in the bound form. The measurement provides the distance 105β-lactamase moves
upon binding to BLIP. PDB codes 1BTL and 2OV5 (apo) and 1JTG and 3E2K (bound). Images generated with Chimera
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residues at position 50 result in a decrease in binding
affinity for all β-lactamases tested, although the effect
is less pronounced for binding KPC-2 (Table 3). This
is supported by the fact that BLIP containing arginine,
glutamate or aspartate at position 50 exhibited decreased
affinity for TEM-1 and Bla1 by greater than 100-fold and
also exhibited decreased affinity for KPC-2 (Table 3). A
proline at position 50 is also generally disruptive in that it
decreased the binding affinity of BLIP for all three β-
lactamases, possibly by altering the conformation or flexi-
bility of the Y50 loop, which includes two hot spot resi-
dues for binding [27].
Fig. 2 Alignment of class A β-lactamase residues at the BLIP interface. a The alignment is based on the structure of class A β-lactamase residues
found at the BLIP interface as defined by the TEM-1/BLIP complex X-ray structure. The positions that contact BLIP position 50 are boxed in red.
PDB codes used for the structural alignment are as follows: 2OV5 for KPC-2, 3QHY for Bla1, 1BTL for TEM-1, 1SHV for SHV-1 and 1DY6 for SME-1.
Structural alignment performed in Chimera [41]. b β-lactamase structures are shown as grey ribbon and were aligned using MacPyMOL. Interface
residues are shown in navy blue with β-lactamase position 105 shown as blue sticks. Residues that make direct contact with Tyr50BLIP (107, 129
and 216) are shown as red sticks. A global structural alignment of TEM-1, Bla1 and KPC-2 β-lactamases is shown in two orientations. c A close-up
view of an alignment of the β-lactamase residues that make contact with Tyr50BLIP. β-lactamase position 105 is also shown as stick model as it has been
shown to make structural rearrangements upon binding to BLIP [14, 16, 35]. d A close up alignment of β-lactamase positions 107, 129, 216 and 105 are
shown with changes in orientation made for ease of viewing the structural alignment. Residues are labeled with their corresponding β-lactamase. PDB
codes used for generation of images were as follows: 1BTL for TEM-1, 3QHY for Bla1 and 2OV5 for KPC-2. Images generated in MacPyMOL
Table 2 Sequence Identity Comparison of Class A β-lactamases
Percent sequence identity
Total protein Interface residues
KPC-2 & TEM-1 38 39
KPC-2 & Bla1 38 52
TEM-1 & Bla1 38 61
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Another common trend for binding all three β-
lactamases is that substitutions of BLIP Y50 by the small
amino acids alanine and glycine either does not affect or
improves affinity (Table 3). For example, BLIP Y50A re-
tains affinity for KPC-2 and Bla1 and exhibits 50-fold tigh-
ter binding of TEM-1 while Y50G shows a small increase
in affinity for all three enzymes. As noted above and shown
in Figs. 1 and 2, Tyr105 in TEM-1 and the equivalent
Trp105 in KPC-2 change position in the BLIP-β-lactamase
complexes compared to the apo-enzymes in order to avoid
a steric clash with BLIP Y50. It is possible that substitution
of Y50 with alanine or glycine avoids the clash and allows
β-lactamase residue 105 to retain its apo-position in the
complex, which may result in improved affinity.
Finally, polar residue substitutions at BLIP Y50 have
quite disparate effects on binding the β-lactamases. For
example, serine and threonine substitutions have rela-
tively small effects on binding KPC-2 and TEM-1 but
result in greatly decreased binding to Bla1 (Table 3). In
addition, glutamine at BLIP position 50 does not affect
binding to any of the β-lactamases while an asparagine
substitution results in decreased affinity for all three β-
lactamases, including a greater than 10-fold decrease for
binding TEM-1 and Bla1 (Table 3). This result cannot
easily be explained because asparagine has similar
properties to glutamine, which had little to no effect
on binding any of the β-lactamases.
Impact of BLIP Y50 on binding specificity
Because the purpose of this study was to examine the
role of BLIP position 50 as a specificity determinant,
substitutions that have differential effects on binding are
of interest. As indicated above and is apparent in
Tables 3 and 4, many substitutions at BLIP Y50 have dif-
ferential effects on β-lactamase binding, the most clear
example being the numerous substitutions that retain or
modestly impact binding to KPC-2 while greatly de-
creasing binding to Bla1 (Y50-L,M,W,N,S,T,H), and the
subset of substitutions that retain binding to KPC-1 and
TEM-1 while losing affinity for Bla1 (Y50-L,M,S,T). In
contrast, there are no BLIP Y50 substitutions that retain
affinity for Bla1 while losing affinity for KPC-2 or TEM-1
(Table 3). Thus, the large differences in stringency of
sequence requirements at position 50 results in BLIP vari-
ants that bind KPC-2 but not TEM-1 and Bla1 as well as
those that bind KPC-2 and TEM-1 but not Bla1. However,
substitutions at BLIP Y50 do not produce a variant that
binds Bla1 but not TEM-1 or KPC-2.
It was next of interest to examine a possible structural
basis for the observed differences in sequence require-
ments for BLIP Y50 substitutions for binding Bla1 versus
KPC-2 and TEM-1. The side chain of BLIP Y50 is in
direct contact with β-lactamase residues 107, 129 and
216 in the crystal structures of the BLIP-TEM-1 and
BLIP-KPC-2 complexes (Fig. 2). These β-lactamase con-
tact residues are identical between KPC-2 and Bla1
(P107-Y129-T216) while TEM-1 differs at 2 of the 3 po-
sitions (P107-M129-V216) (Fig. 2). Based on these se-
quences, it would be expected that substitutions at BLIP
Y50 would have similar effects on binding KPC-2 and
Bla1. The results indicate this is clearly not the case.
Therefore, a simple comparison of the β-lactamase
contact residues for BLIP Y50 does not explain the ob-
served differences in effects of substitutions on binding
the β-lactamases. Although KPC-2 and Bla1 have the
same amino acids at positions 107, 129 and 216, the
overall sequence identity of all β-lactamase residues at
the interface is higher between Bla1 and TEM-1 com-
pared to KPC-2 (Table 2). There are a total of 10 po-
sitions (71, 102, 106, 109, 112, 133, 172, 246, 248 and
249) on the β-lactamase interface where TEM-1 and
Bla1 have the same sequence and the sequence of
KPC-2 differs (Fig. 2). KPC-2 is much better at ac-
commodating changes at BLIP Y50 than both Bla1
and TEM-1 and has the most sequence differences at
the interface. Therefore, more widespread differences
in the entire interface may influence the effect of sub-
stitutions at BLIP Y50. This may be due to changes
at the interface induced by mutation of BLIP Y50 that
propagate outside of its local environment. In fact,
previous studies have shown that BLIP Tyr50 is ener-
getically coupled to both positions Tyr143 and Glu73,
Table 3 Inhibition Constants of BLIPY50 mutants for Class A β-
lactamases
BLIP Mutant Ki (nM) KPC-2 Ki (nM) TEM-1 Ki (nM) Bla1
Nonpolar WT 1.5 ± 0.2 0.5 ± 0.1 2.5 ± 0.3
Y50A 1.9 ± 0.3 0.010 ± 0.001 1.2 ± 0.3
Y50F 15 ± 2 10.3 ± 0.8 90 ± 14
Y50L 0.7 ± 0.2 0.17 ± 0.02 160 ± 39
Y50M 0.5 ± 0.1 0.11 ± 0.01 34 ± 9
Y50V 10 ± 1 3.5 ± 0.6 200 ± 11
Y50W 1.1 ± 0.2 11 ± 1 90 ± 11
Polar Y50C 42 ± 6 60 ± 10 360 ± 5
Y50N 3.8 ± 0.8 7.8 ± 0.5 180 ± 43
Y50Q 1.0 ± 0.5 0.24 ± 0.02 1.3 ± 0.3
Y50S 5 ± 1 1.1 ± 0.1 3110 ± 5
Y50T 3.5 ± 0.4 2.5 ± 0.2 290 ± 53
Small Y50G 0.72 ± 0.02 0.40 ± 0.06 0.58 ± 0.07
Y50P 5 ± 1 40 ± 3 220 ± 28
Charged Y50H 1.4 ± 0.1 5.0 ± 0.1 230 ± 2
Y50R 11 ± 1 69 ± 2 >1500
Y50K 260 ± 10 195.3 ± 0.2 180 ± 47
Y50D 3.2 ± 0.3 160 ± 23 >4500
Y50E 5.5 ± 0.1 76 ± 6 331 ± 6
BLIP Y50I could not be purified
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which are not in direct contact with Tyr50 [13]. The
hypothesis that changes at position 50 are influenced
by other sites in the interface and vice versa is con-
sistent with previous observations of structural plasti-
city and cooperativity of the BLIP interface upon mutation
[12, 13, 15, 16, 27]. For example, it has been shown that
the BLIP W150A mutation induces a greater than 4 Å
shift in residue Asp49, demonstrating both structural
flexibility of the loop containing Tyr50 and long distance
coupling at the BLIP interface [28].
An interesting question is whether there are also
more stringent sequence requirements at other BLIP
positions in the interface for binding Bla1 versus
TEM-1 and KPC-2. A previous alanine-scanning mu-
tagenesis study for 23 BLIP residues that contact β-
lactamase in the bound complex evaluated binding to
TEM-1 and Bla1 (KPC-2 was not evaluated) [27]. The
results of this study suggest that the sequence re-
quirements are not generally more stringent for BLIP
binding Bla1 in that the average ΔΔG effect for the
23 alanine substitutions was less detrimental for bind-
ing Bla1 (avg ΔΔG = 0.4) than for TEM-1 (avg ΔΔG =
1.0) [27]. Therefore, the stringent sequence require-
ments observed here for Bla1 binding are unique to
position 50 and not a general property of all interface
positions for binding Bla1.
Fig. 3 Determination of inhibition constants of BLIP mutants for binding TEM-1, KPC-2 and Bla1. The concentration of BLIP is shown on a log
scale on the x-axes and fractional initial velocity is shown on the y-axes. Inhibition curves are shown for wild type BLIP in black. Inhibition curves
for BLIP mutants that showed tighter binding than wild type are shown in blue while curves for mutants that showed weaker binding are shown in red
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Comparison of experimental and predicted ΔΔG values
It is appealing to use computational methods to guide
engineering of binding specificity in protein-protein in-
teractions. Therefore, we were interested to examine
how computational methods compared to our experi-
mental results. The same mutagenesis experiment was
performed computationally on BLIP position 50 with the
BeAtMuSiC server, which computes theoretical ΔΔG
values based on a set of statistical potentials derived
from known protein structures [11]. The TEM-1-BLIP
(PDB code: 1JTG) and KPC-2-BLIP (PDB code: 2OV5)
complexes were submitted for analysis. The BLIP-Bla1
interaction was not analyzed because there is currently
no crystal structure available of this complex.
The ΔΔG values generated by the BeAtMuSiC server
and the experimentally determined ΔΔG values are plotted
in Fig. 5. The average predicted ΔΔG value for the TEM-
1/BLIP interaction was 2.0 kcal/mol while the experimen-
tally determined average ΔΔG value was 1.3 kcal/mol. For
the KPC-2-BLIP interaction, the average predicted ΔΔG
was 2.2 kcal/mol and the experimentally determined aver-
age ΔΔG was 0.7 kcal/mol. Therefore, the BeAtMuSiC ser-
ver was more accurate at predicting ΔΔG values for the
BLIP-TEM-1 interaction than the BLIP-KPC-2 interaction.
Discussion
Specificity determinants are often identified through ala-
nine scanning of interface residues [16–18, 29, 30].
Fig. 4 Comparison of ΔΔG values of BLIP mutants for binding TEM-1, KPC-2 and Bla1 β-lactamases. BLIP Y50X mutants are shown on the x-axis and the
calculated change in free energy is shown on the y-axis. Values for TEM-1 are shown in black, KPC-2 in white and Bla1 in gray










Nonpolar Y50A 0.14 ± 0.03 -2.4 ± 0.5 -0.44 ± 0.07
Y50F 2.2 ± 0.4 1.8 ± 0.4 1.4 ± 0.3
Y50L -0.5 ± 0.1 -0.6 ± 0.2 2.5 ± 0.7
Y50M -0.7 ± 0.2 -0.9 ± 0.2 1.6 ± 0.5
Y50V 1.1 ± 0.2 1.2 ± 0.3 2.7 ± 0.4
Y50W 1.2 ± 0.3 1.9 ± 0.4 2.1 ± 0.4
Polar Y50C 2.0 ± 0.4 2.9 ± 0.7 3.0 ± 0.4
Y50N 0.6 ± 0.1 1.7 ± 0.3 2.6 ± 0.7
Y50Q -0.2 ± 0.1 -0.4 ± 0.1 -0.4 ± 0.1
Y50S 0.7 ± 0.2 0.5 ± 0.1 4.3 ± 0.5
Y50T 0.51 ± 0.09 1.0 ± 0.2 2.9 ± 0.6
Small Y50G -0.44 ± 0.06 -0.13 ± 0.03 -0.9 ± 0.2
Y50P 0.7 ± 0.2 2.6 ± 0.6 2.7 ± 0.5
Charged Y50H 0.042 ± 0.006 1.4 ± 0.3 2.7 ± 0.3
Y50R 1.2 ± 0.2 3.0 ± 0.6 >3.9
Y50K 3.1 ± 0.4 3.6 ± 0.7 2.6 ± 0.7
Y50D 0.46 ± 0.07 3.5 ± 0.9 >4.5
Y50E 0.8 ± 0.1 3.0 ± 0.7 2.9 ± 0.4
BLIP Y50I could not be purified
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Whether mutations to other amino acids would also
identify these residues as specificity determinants is un-
known. Here, we present data supporting the role of
BLIP Y50 as a specificity determinant and furthermore,
provide evidence that this position can be targeted to
engineer binding specificity of BLIP for a range of class
A β-lactamases.
The BeAtMuSiC server did not predict any negative
changes in free energy meaning that the energy of the
wild-type complex is predicted to be more stable than
Fig. 5 Comparison of experimental and predicted ΔΔG values for BLIP Y50 variants. A comparison of the experimental and predicted ΔΔG values
of the BLIP Y50X mutants for binding TEM-1 are shown on the top panel. A comparison of the experimental and predicted ΔΔG values of the BLIP
Y50X mutants for binding KPC-2 are shown on the bottom panel. The BeAtMuSiC server was used to generate predicted ΔΔG values. The predicted
values are shown in red and the experimental values are shown in black
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any of the mutants. However, the BLIP Y50A substitu-
tion was shown experimentally to bind TEM-1 β-
lactamase 50-fold tighter than wild type BLIP. It is
known that some residues rearrange upon binding of
BLIP and class A β-lactamases and this could influence
the accuracy of the prediction programs [27]. These
rearrangements could play into the differences seen
(about 1.4 kcal/mol) between our experimental ΔΔG
values and the predicted values. Furthermore, BLIP Y50
is located on a loop that has two hot spots for binding;
therefore, even small alterations in the placement of this
loop induced by Y50 substitutions could result in large
changes in binding affinity. In addition, as described
above, the effect of substitutions at BLIP Y50 may be in-
fluenced by positions outside of the direct contact resi-
dues through coupled interactions and therefore
predictions of effects of substitutions poses a significant
challenge for computational prediction programs. How-
ever, it may be these same properties that provide BLIP
with its unique ability to bind structurally homologous
proteins with a wide-range of affinities.
Because BLIP binds homologous β-lactamase struc-
tures that only differ by small changes in sequence at
the interface, the BLIP-β-lactamase system is useful for
examining how sequence dictates binding affinity. How-
ever, an alignment of the β-lactamase sequences in direct
contact with the BLIP Y50 residue (TEM-1 residues 107,
129 and 216) suggests that KPC-2 and Bla1 would ex-
hibit the same changes in binding affinity upon mutation
of BLIP Y50 because they have the same amino acids in
similar conformations at these positions; however, this
was not the case (Fig. 2). Although KPC-2 and Bla1 have
the same amino acids at positions 107, 129 and 216 that
directly interact with Y50, the overall sequence identity
of all β-lactamase residues at the interface is higher be-
tween Bla1 and TEM-1 compared to KPC-2 (Table 2).
KPC-2 was much better at accommodating changes at
BLIP Y50 than both Bla1 and TEM-1 and had the most
sequence differences at the interface. This suggests that
simply comparing sequence identity of positions that
make direct interactions with BLIP Y50 (or any BLIP
residue) is not sufficient to predict changes in binding
affinity upon mutation. Therefore, more widespread dif-
ferences in the entire interface may influence the effect
of substitutions at BLIP Y50. This may be due to
changes at the interface induced by mutation of BLIP
Y50 that propagate outside of its local environment due
to structural plasticity and coupled interactions.
Conclusions
Properties such as structural plasticity and cooperativity
between residues are important for mediating protein
interactions and critical for allosteric regulation in vari-
ous cell processes [31–34]. Understanding how these
properties contribute to binding specificity would greatly
improve current protein binding prediction programs.
This is an active area of investigation in G-protein
coupled receptors, the human growth hormone receptor
and other proteins [31–34]. Numerous studies such as
these have established that the dynamic nature of pro-
teins is critical to binding and proper functioning; how-
ever, this dynamic nature is challenging to predict and
structurally understand, as flexible proteins are inher-
ently difficult to model and crystallize. Here, we demon-
strate the complexity of predicting the impact of
substitutions using the well-studied BLIP-β-lactamase
protein-protein interaction model. Furthermore, we have
shown that surveying sequence homology and the struc-
tural interface of a complex are not sufficient in predict-
ing the impact of mutations.
Currently, protein prediction programs are unable to
reliably predict changes in binding affinity upon muta-
tion at the protein interface. Systematic studies such as
these could improve the current state by providing
experimental data to be incorporated into these pro-
grams. Lastly, there is a pressing need for new detection
methods for β-lactamases, which are a widespread
source of resistance to β-lactam antibiotics. Identifica-
tion of specificity determinants in BLIP could be useful
in the development of BLIP-based diagnostic reagents
that can discriminate between class A β-lactamases and
inform treatment options for clinicians.
Methods
Construction of BLIP Y50 mutants
BLIP position 50 was mutated to all 19 amino acids
using the Quickchange method (Stratagene) and Pfu
polymerase (Stratagene) on the pGR32 plasmid with an
N-terminal His-tag as previously described [35]. DNA
sequencing was used to confirm the mutations and that
no extraneous mutations occurred elsewhere on the
BLIP gene in each of the mutants (Lonestar Labs).
Protein purification
N-terminal His-tagged BLIP mutants were purified using
the TALON Metal Affinity Resin (Clontech) [35]. Des-
pite multiple attempts, the BLIP Y50I mutant could not
be purified due to poor expression and yield. The TEM-
1 and Bla1 proteins were purified as previously described
using a zinc chelating column and elution with a pH
gradient [36]. KPC-2 was purified as previously de-
scribed using a HiTrap SP column and elution with an
NaCl gradient [37]. The BLIP mutants and the various
β-lactamases were each concentrated and injected onto
a Superdex 75 gel filtration size exclusion column as a
final purification step. Fractions with greater than 90%
purity as determined by SDS-PAGE were combined,
concentrated and used in the inhibition assay. The
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protein concentrations for the β-lactamases and BLIP
mutants were determined by a Bradford assay where
they were compared with a curve that was calibrated by
quantitative amino acid analysis specific to each protein.
The concentrations for all proteins were confirmed by
measuring absorbance at 280 nm and using the ex-
tinction coefficient as determined by the ExPASy
ProtParam tool [38]. Kinetic parameters (kcat and Km)
were determined to confirm activity for each β-
lactamase using the chromogenic β-lactam substrate,
nitrocefin (data not shown).
β-lactamase inhibition assay
Inhibition constants for BLIP mutants binding to the β-
lactamases were determined as previously described
[35]. Increasing concentrations of BLIP were incubated
with a constant concentration of β-lactamase (1 nM) for
1 h at room temperature in 50 mM sodium phosphate
buffer pH 7.0. The chromogenic substrate, nitrocefin,
was then added at the Km concentration for the β-
lactamases and the initial velocity was measured at
482 nm in 20 s intervals. The experiments were per-
formed in at least duplicate. The Ki
app for each BLIP mu-
tant was determined by fitting the initial velocities to the
Morrison tight-binding equation [39]:
Efree¼ E0½ −
E0½  þ I0½  þ K appi −
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
E0½  þ I0½  þ K appi




where Efree is the concentration of free enzyme deter-
mined by residual activity of the β-lactamase by com-
parison with the initial velocity of nitrocefin hydrolysis
by the uninhibited β-lactamase, [E0] is the total enzyme
concentration and [I0] is the total BLIP concentration.
The errors reported were calculated based on the fit of
the curve. The Ki values were calculated from the Ki
app
values as previously described using eq. 2 [40]:
Ki ¼ Kiapp= 1þ S½ =KMð Þð Þ ð2Þ
ΔΔG calculations
ΔΔG was calculated using the following equation:
ΔΔG ¼ − RT ln KWTi =KMUTi
  ð3Þ
Using this equation, a decrease in Ki upon mutation
would result in a negative ΔΔG value while an increase
in Ki would be reported as a positive change in free en-
ergy. Error for ΔΔG values was calculated using the fol-
lowing equation:









Where ‘SEM’ represents standard error of the mean,
‘WT’ represents wild-type BLIP and ‘MUT’ represents
the mutant protein.
Computational prediction of the effect of BLIP mutations
on binding affinity
The BeAtMuSiC online server was used to predict
changes in binding affinity of the BLIP mutants on com-
plex formation with TEM-1 and KPC-2 β-lactamases
[11]. The BeAtMuSiC server relies on a set of statistical
potentials derived from known protein structures and
predicts the changes in binding affinity by the combined
effect of the mutation on the overall stability of the com-
plex and the interface [11]. PDB codes 1JTG (BLIP/
TEM-1) and 3E2K (BLIP/KPC-2) (chains A and B) were
submitted for analysis.
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